Most Recent

image: The Growth of Iowa Biotech

The Growth of Iowa Biotech

By | August 1, 2016

The state’s industry draws inspiration from medicine as well as agriculture.

1 Comment

image: Banking on Blood Tests

Banking on Blood Tests

By | April 1, 2016

How close are liquid biopsies to replacing current diagnostics?

1 Comment

image: Desperately Seeking Shut-Eye

Desperately Seeking Shut-Eye

By | March 1, 2016

New insomnia drugs are coming on the market, but drug-free therapy remains the most durable treatment.

0 Comments

image: Picking Up the Pace

Picking Up the Pace

By | January 1, 2016

FDA designations promise to expedite the approval of drugs for conditions ranging from infectious disease to cancer.

0 Comments

image: Battling the Bulge

Battling the Bulge

By | November 1, 2015

Weight-loss drugs that target newly characterized obesity-related receptors and pathways could finally offer truly effective fat control.

0 Comments

image: The Sounds of Silence

The Sounds of Silence

By | September 1, 2015

Science-based tinnitus therapeutics are finally coming into their own.

3 Comments

image: Clinical Matchmaker

Clinical Matchmaker

By | June 1, 2015

Enrolling the right patient population could be key to a successful clinical trial.

0 Comments

image: The CAR T-Cell Race

The CAR T-Cell Race

By | April 1, 2015

Tumor-targeting T-cell therapies are generating remarkable remissions in hard-to-beat cancers—and attracting millions of dollars of investment along the way.

1 Comment

image: Cannabis Biotech

Cannabis Biotech

By | December 1, 2014

As medical marijuana businesses set up shop across the U.S., a handful of companies are taking the pharmaceutical route, guiding cannabis-derived drugs through clinical trials.

2 Comments

image: Eyes on the Prize

Eyes on the Prize

By | October 1, 2014

A handful of stem cell therapeutics for vision disorders are showing promise in early-stage trials, and still more are in development. But there’s a long road to travel before patients see real benefit.  

3 Comments

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. How Plants Evolved Different Ways to Make Caffeine
  3. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

  4. Another DNA Vaccine for Zika Shows Promise
RayBiotech